Resources

Awareness of Nucleic Acid-Based Therapies

Home | Resources

In this Syndicated Report we had two goals:

  • Provide a baseline understanding of current knowledge among physicians regarding the types of nucleic acid-based therapies, their mechanisms of action, and their current and future promise.
  • Serve as a vehicle for future surveys to assess how knowledge and perceptions change over time.

Methodology: 12-Minute MicroSurvey
Crowds: PCPs, Oncologists, & Pediatricians
Sample Size: n=250
Fielding Period: September 8-10, 2019

This report explores physician awareness of the following RNA- or DNA-based therapeutic methods:

  • RNAi (RNA interference)
  • siRNA (short interfering RNAs)
  • ASO (antisense oligonucleotides)
  • mRNA (messenger ribonucleic acid)
  • AAV (adeno-associated virus)
  • CRISPR (clustered regularly interspaced short palindromic repeats)
  • TALENs (transcription activator-like effector nuclease)

Download the report now!

Please fill out the form below to access this content

Related Resources

IV Fluid Supply Chain Disruptions 

IV Fluid Supply Chain Disruptions 

Discover the Impact of Hurricane Helene on IV Fluid Availability When Hurricane Helene disrupted a key IV fluid manufacturing facility in the southeastern US, healthcare systems felt the ripple effects. InCrowd conducted research to uncover how this shortage has...

read more
Physician Burnout: Knowing Your Audience 

Physician Burnout: Knowing Your Audience 

Physician Engagement in a Time of Accelerated Professional Burnout  As burnout remains a significant challenge for healthcare professionals (HCPs), emerging research indicates a potential shift in this landscape. Our newest report unveils insights from a recent...

read more
ASH 2023 Post-Event Round-Up 

ASH 2023 Post-Event Round-Up 

Reactions and Insights from Hematologists and Hematology-Oncologists at ASH 2023  In December 2023, the American Society of Hematology (ASH) held its Annual Meeting, and InCrowd conducted a 1-minute MicroSurvey to gather insights from 100 US-based Hematologists and...

read more